A retrospective clinical study in Graves disease with COVID-19 infection in China

Abstract Background Corona Virus Disease 2019 (COVID-19) is the most prevalent global pandemic in recent times. Graves disease (GD), an autoimmune thyroid disease, is a clinical syndrome caused by excessive thyroid hormones. Our study is to understand the current epidemiological situation of COVID-19 infection in GD patients, and to analyze whether COVID-19 will affect the thyroid function, thyroid autoantibody and metabolism of GD patients. Methods 109 GD patients were followed by Shanghai General Hospital Thyroid Disease Center (TDC) from November 2022 to June 2023. There were three groups defined, i.e., pre, one-month after and three months after infection with COVID-19. SPSS was used to analyze the recruited data. Results 109 GD patients are infected with COVID-19 (72.48%), uncontrolled GD patients with high FT3 had a higher COVID-19 infection rate (79.31%). As for thyroid function in 35 GD patients with antithyroid drug (ATD) maintenance stage, there were significant differences in FT3, FT4, TT3 and TT4 before and after being infected with COVID-19. What’s more, there’s a significant difference between GD patients in one month and three months after COVID-19 infection of high TSAb group ( p = 0.048) but no significant difference between pre and one month. What’s more, there were significant differences in TT3, TT4 of GD patients after infected COVID-19 in non. And Phosphorus (P), 25-hydroxyvitamin D (25-OH-D3), Procollagen type 1 N-terminal propeptide (P1NP) in GD patients were be affected by COVID-19 infection. Conclusion GD patients with uncontrolled thyroid function group are susceptible to COVID-19. COVID-19 may affect the thyroid function of GD in TT3, TT4, TSAb high level group infection. COVID-19 vaccine is conducive to the stability of GD patients' condition. And COVID-19 may affect the bone metabolism in GD patients before and after COVID-19 infection. But there is no effect on glucose metabolism or lipid metabolism.